SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

An alleged early leak of Phase 3 results for Moderna and Mercks personalized melanoma vaccine triggered a sharp selloff ahead of the full data presentation. Traders disagree over whether the reported benefit is clinically meaningful but fell short of elevated expectations, and some question the leaks accuracy while others expect more volatility around the full readout.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCXs sharp pullback after its earnings-driven jump is being attributed mainly to a large share unlock that traders fear will add selling pressure, alongside broader tech weakness and concerns about heavy spending and a possible Tesla tie-up. The earnings beat has not eased the bearish reaction, though some investors view the decline as a buying opportunity.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp selloff in semiconductor and technology stocks has pushed SOXL to a six-month low, with its 3x daily leverage amplifying the decline. Traders are split between seeing AI-funding concerns and broader market pressure as signs of further downside, and treating the drop as an oversold buying opportunity.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention amid a sharp tech-led selloff, with traders focused on worries about AI spending and credit availability, weakness in semiconductors, and elevated oil prices tied to Iran tensions. The conversation is largely bearish, though some traders see an oversold dip-buying opportunity or expect a rebound.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

AMZNs sharp decline is being discussed largely alongside selling across mega-cap tech and hyperscalers, with traders also questioning whether heavy AI and data-center spending could pressure cash flow ahead of earnings. Reactions are split between dip buyers calling the drop excessive and bearish traders anticipating further weakness; no single confirmed company-specific catalyst dominates.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokias Q3 results beat expectations and AI/cloud demand surged, but shares sold off sharply as traders focused on negative free cash flow, a lower cash-conversion outlook, higher restructuring costs and supply-chain cost pressure. Bulls call the reaction an overreaction and point to AI and network growth, while bears argue cash generation and the outlook matter more than the headline beat.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is drawing attention after a sharp month-long slide amid weakness across semiconductor and AI stocks, with traders also focused on its test of the 200-day moving average and upcoming earnings. Some view the selloff as an oversold buying opportunity near support, while others warn that the decline could continue; the cause is not settled in the discussion.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas sharp selloff after its quarterly results is being linked to rising AI infrastructure spending, negative free cash flow, and concerns that the new nonvoting share class could enable future fundraising and dilute shareholders, despite strong advertising performance and upbeat guidance. Traders are split between viewing the drop as a buying opportunity and questioning whether AI investments can generate enough returns to justify the costs.

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

Forgents CFO departure, with finance executive Amy Ard taking over, is driving the sharp selloff and concerns among traders that the change could signal undisclosed financial problems; those concerns remain speculation. The community is split between calling the decline an overreaction and buying on the companys data-center and power-grid growth prospects, and waiting for management to clarify the situation.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is caught in a sharp semiconductor and tech selloff, alongside broader Nasdaq weakness, as traders debate stretched AI valuations, data-center spending returns, and macro risks. Some see the decline as an oversold dip-buying opportunity ahead of earnings, while others warn of a deeper AI-sector correction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Skye Bioscience (SKYE) Shares Rise 6% After Hours: Here's What's Driving The Move

Skye Bioscience shares rise 6% after hours on a $22M equity purchase agreement and warrant issuance.read more...

Why HIVE Digital Technologies Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket

HIVE Digital Technologies Ltd (NASDAQ: HIVE) rose in pre-market trading due to its subsidiary's new agreement. Other gainers include IP Strategy Holdings, INVO Fertility, My Size, Trugolf Holdings, Expion360, Skye Bioscience, Julong Holding, FIEE Inc, and Keel Infrastructure. Losers include...

Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE

Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SKYE Skye Bioscience, Inc. Sued for Securities Law Violations - Contact the DJS Law Group...

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit with the Schall Law Firm SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit...

SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit

SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit SKYE Deadline: SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud...

Class Action Filed Against Skye Bioscience, Inc. (SKYE) - January 16, 2026 Deadline to Join - Contact The Gross Law Firm

Class Action Filed Against Skye Bioscience, Inc. (SKYE) - January 16, 2026 Deadline to Join - Contact The Gross Law Firm Class Action Filed Against Skye Bioscience, Inc. (SKYE) - January 16, 2026...

SKYE Deadline: Rosen Law Firm Urges Skye Bioscience, Inc. (NASDAQ: SKYE) Stockholders to Contact the Firm for Information About Their Rights

Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Skye Bioscience, Inc. (NASDAQ: SKYE) between November 4, 2024 and October 3, 2025. Skye is a clinical stage...

Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 16, 2026 to Discuss Your Rights - SKYE

Skye Bioscience, Inc. Securities Fraud Class Action Lawsuit Pending: Contact The Gross Law Firm Before January 16, 2026 to Discuss Your Rights - SKYE Skye Bioscience, Inc. Securities Fraud Class...

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit

SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit SKYE Investors Have Opportunity to Lead Skye Bioscience, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK...

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm

Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm Kuehn Law Encourages Investors of Skye Bioscience, Inc. to Contact Law Firm PR Newswire NEW YORK, Jan. 6, 2026 NEW YORK...

Skye Bioscience, Inc. is a clinical stage biopharmaceutical company, which engages in the business of research and development activities related to developing medicine for obesity and metabolic diseases. Its products include nimacimab and SBI-100 Ophthalmic Emulsion. The company was founded on March 16, 2011 and is headquartered in San Diego, CA.

Skye Bioscience Inc

Why Did Skye Bioscience Stock Plummet A Whopping 60% Today?

Equity

Neutral Sentiment

Shares of Skye Bioscience, Inc. (SKYE) dived 60% in the pre-market session on Monday after the company said that its Nimacimab alone did not cause weight loss as compared to placebo in a mid-stage trial.Preliminary analysis suggested that 200 mg of Nimacimab as a subcutaneous weekly dose was suboptimal as a monotherapy, the company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.skyebioscience.com/news-releases/detail/244/skye-bioscience-reports-topline-cbeyond-phase-2a-data-from-nimacimab-monotherapy-and-combination-clinical-trial">said</a>. The data, however, support the evaluation of higher dosing, the company said.Further, Nimacimab in combination with Novo Nordisk’s Semaglutide demonstrated a clinically meaningful magnitude of weight loss compared to Semaglutide alone, the company said. The positive observation supports further studies where Nimacimab is used with other therapies, it added.The drug alone and in combination demonstrated a clean safety profile, with no added gastrointestinal adverse events and no increases in neuropsychiatric adverse events reported resulting from treatment with Nimacimab, Skye said. Overall, the study, which enrolled 136 adults with overweight or obesity, had a discontinuation rate of 27%. Notably, 3.7% of the discontinuations were due to adverse events, with the placebo group contributing 60% of these discontinuations, according to the company.“With our preclinical data, toxicology safety margins, and PK modeling, we believe we have a path to support higher dosing, and we are evaluating the next stage of development to optimize dosing in potential future clinical trials," said Puneet Arora, Chief Medical Officer of Skye Bioscience. The company is now evaluating the data to determine the next steps for the development of the drug.SKYE stock is up 68% this year and by about 24% over the past 12 months.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

The company stated that its investigational drug alone did not cause weight loss compared to the placebo in a mid-stage trial. 

iShares Micro-Cap ETF

Vanguard Extended Market ETF

Very bullish

Cautiously bullish

Cautiously bearish

Very bearish

Stocktwits sentiment on $SPY just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits

 just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits Polls

$SKYE I owned SKYE when it embi and it switched to skye

Can someone please explain to me why I keep checking on it and posting here

It’s like the sun - I can’t not look at it

Feed

News

Sentiment

Earnings

Fundamentals

Info

SKYE Skye Bioscience Inc

Fundamentals

Latest SKYE News